Mineralys Therapeutics (MLYS) Change in Accured Expenses (2022 - 2026)
Quarterly results put Change in Accured Expenses at -$402000.0 for Q1 2026, up 74.0% from a year ago — trailing twelve months through Mar 2026 was $1.6 million (up 127.16% YoY), and the annual figure for FY2025 was $427000.0, down 89.74%.
Mineralys Therapeutics has reported Change in Accured Expenses over the past 5 years, most recently at -$402000.0 for Q1 2026.
- Change in Accured Expenses reached -$402000.0 in Q1 2026 per MLYS's latest filing, up from -$8.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $9.5 million in Q2 2024 and bottomed at -$16.7 million in Q4 2024.
- Median Change in Accured Expenses over the past 5 years was $864000.0 (2022), compared with a mean of $565588.2.
- Peak annual rise in Change in Accured Expenses hit 2627.14% in 2023, while the deepest fall reached 465.15% in 2023.
- Over 5 years, Change in Accured Expenses stood at $846000.0 in 2022, then crashed by 461.82% to -$3.1 million in 2023, then crashed by 444.72% to -$16.7 million in 2024, then skyrocketed by 51.24% to -$8.1 million in 2025, then skyrocketed by 95.06% to -$402000.0 in 2026.
- Business Quant data shows Change in Accured Expenses for MLYS at -$402000.0 in Q1 2026, -$8.1 million in Q4 2025, and $1.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 107.70 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | -402,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -402,000.00 |
| Mar 31, 2026 | -402,000.00 |
| Dec 31, 2025 | -8.13 Mn |
| Dec 31, 2025 | -8.13 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 9.07 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Dec 31, 2024 | -16.67 Mn |
| Dec 31, 2024 | -16.67 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 9.47 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Dec 31, 2023 | -3.06 Mn |
| Dec 31, 2023 | -3.06 Mn |
| Sep 30, 2023 | 7.34 Mn |
| Sep 30, 2023 | 7.34 Mn |
| Jun 30, 2023 | -3.77 Mn |
| Jun 30, 2023 | -3.77 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Dec 31, 2022 | 846,000.00 |
| Dec 31, 2022 | 846,000.00 |
| Sep 30, 2022 | 269,000.00 |
| Sep 30, 2022 | 269,000.00 |
| Jun 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 864,000.00 |
| Mar 31, 2022 | 864,000.00 |